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INTRODUCTION 
Since the initial recognition of COVID-19 in the world in 
2019, tremendous advances have taken place in the 
understanding of the dreaded diseases as regarding its 
epidemiology, etiology, immunology, Pathophysiology, 
clinical feature, and morphology changes in various 
tissues and organs of the body. Although antiretroviral 
therapy is being widely used all over the world for such 
patents, effects at finding a 2019 Novel Coronavirus 
(SARS-CoV-2) vaccine have not succeeded. Human 
pathogenic subtypes of a coronavirus are associated with 
mild clinical manifestations. However, SARS-CoV and 
MERS-CoV are two important exceptions. In 2012, 
MERS-CoV was first seen in Saudi Arabia. He was 
responsible for 2,494 confirmed cases, leaving 858 people 
dead. In 2002, a subtype of the Corona beta virus spread 
rapidly in Guangdong, China. This epidemic has claimed 
8,000 deaths and 774 deaths in 37 countries (Lu et al., 
2020). The epidemic of 2020 was detected as pneumonia 
of unknown etiologic in Wuhan, China. Extensive 
studies and laboratory research have identified the 
offender as a new strain of a coronavirus (Adhikari et al., 
2020). 
Initially, this virus was classified as SARS-CoV-2. 
However, the virus was classified by the International 
Commission for Viruses Classification as CoV-2. On 
February 11th, 2020, the World Health Organization 
(WHO) announced that the disease caused by this new 
virus was Coronavirus 2019 (COVID-19). The emergence 
and outbreak of frequent coronaviruses pose a public 
health threat. This recommends that CoVs that originate 
from one animal to another can be transferred from one 
person to another. The ongoing changes in the 
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 Abstract 
Initially recognized of COVID-19 within the world in 2019, the World 
Health Organization situational report from May 22nd, 2020, globally, 
there is a complete of 5,204,508 confirmed cases, with 212 countries 
being affected by the novel coronavirus. 2019 novel coronavirus 
(SARS-CoV-2) is that the seventh member of the family of 
coronaviruses is enveloped viruses with a positive sense, single-
stranded RNA genome. The SARS-CoV-2 may be a β-CoV of group 2B 
there is 70% comparability in genetic sequence to SARS-CoV. The 
source of the new coronavirus infection has been resolved as bats. 
With whole-genome sequences of SARS-CoV-2 is 96% comparatively 
at the whole-genome level to a bat coronavirus. Mechanisms of 
transmission are concluded to incorporate contact, droplet, and 
possibly airborne under certain circumstances supported ancient 
experiences associated with SARS-CoV outbreaks. Although 
antiretroviral therapy is being widely used everywhere the globe for 
such patents, effects at finding a SARS-CoV vaccine haven’t succeeded 
so far. 
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environment and climate make the emergence of such 
infections in the future more likely (Hassan et al., 2020). 
 
EPIDEMIOLOGY 
COVID-19 is pandemic in the spread and is seen in all 
continents. As per the WHO global report 2019, a novel 
coronavirus recognizing SARS-CoV-2. This is likely the 
third time in three decades that a zoonotic coronavirus 
has fall from infecting animals to humans. As of May 25th, 
2020, 337,687 have died, and 5,204,508 have been infected 
globally with the center of the outbreak being located in 
Wuhan but now having spread, with confirmed cases 
212 other countries (Worldometer, 2020). While the 
fatality rate of SARS-CoV-2 is less than other recent 
respiratory virus outbreaks, it rests much higher than 
other commonly encountered causes of respiratory 
infection but its full impact is yet undetermined. The 
WHO has now conformed the coronavirus outbreak to 
be a public health emergency of international concern 
(Long & Ehrenfeld, 2020). Most infected countries' data of 
COVID-19 are summarized in Figure 1. 
 
Figure 1. COVID-19 spread and is seen in all continents per 
May 25th, 2020 (Worldometer, 2020) 
Many studies show more clearly that the death rate 
increases with age, and children younger than 9 years do 
not appear to be affected significantly, without 
symptoms or mild symptoms or none of them died due 
to a COVID-19 infection. For 80-year-olds, about 14.80% 
of people die as presented in Figure 2. Mortality begins to 
increase for those over 50 years of age. The death rate 
among people under fifty is 0.02%, while it is 0.8% for 
those aged 18-44. For ages 45 to 64 years, the ratio is 
3.60%, for ages 65 to 79 years is 8.00% and for people over 
80 years old is 14.8% (Worldometer, 2020). 
 
Figure 2. The COVID-19 death rate in different age groups per 
May 25th, 2020 (Worldometer, 2020) 
 
The elderly and young people, who suffer from serious 
diseases, such as diabetes and heart and lung diseases, 
are at risk of developing a serious disease if they have a 
coronavirus. The death rate for those without pre-
existing conditions is around 1%. The Centers for Disease 
Control and Prevention has published specific guidelines 
for people in these categories (Hafeez et al., 2020). For 
people with cardiovascular disease, the death rate is 
13.2%, for diabetes 9.2%, for chronic respiratory diseases 
(such as asthma and chronic lung disease) 8.0%, for high 
blood pressure (high blood level) 8.4%, and the cancer 
death rate 7.6%. The data is summarized in Figure 3. 
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Figure 3. COVID-19 death rate by pre-existing health 
condition per May 25th, 2020 (Worldometer, 2020) 
 
ETIOLOGICAL OF COVID-19 
COVID-19 is caused by a single-stranded RNA 
(retrovirus) virus called the 2019 Novel Coronavirus 
(SARS-CoV-2). The 2019 Novel Coronavirus or 2019-
nCoV is called the Wuhan Virus because it is a never 
before seen mutation of an animal coronavirus first 
identified in Wuhan, China, on December 30th, 2019. The 
SARS-CoV-2 is a novel human coronavirus in further to 
similar coronavirus 229E, NL 63, OC43, HKU1, Middle 
East respiratory syndrome-related coronavirus (MERS-
CoV) and severe acute respiratory syndrome-related 
coronavirus (SARS-CoV) (Zhu et al., 2020). The SARS-
CoV-2 is the seventh member of the coronavirus family 
(Nidovirales arrangement, Coronaviridae family, and 
Coronavirinae subgroup) are positive-encapsulated 
viruses, single-chain RNA genome. With genome sizes 
feeding on 26 to 32 kb in length, coronaviruses possess 
the largest genomes of human RNA viruses, after MERS-
CoV and SARS-CoV (Dhama et al., 2014; Hui et al., 2020). 
Thanks to the genome sequencing, the nCoV 2019 gene 
sequencing became available to the WHO, which 
enabled various laboratories to produce a diagnostic test 
for the reverse transcription of a polymerase chain 
reaction (RT-PCR) specifically for detection of 'viral 
DNA. The SARS-CoV-2 is the 2B β-CoV group. With 
genetic comparability of more than 70% with SARS-CoV 
(Li et al., 2020). Coronaviruses have begun two large-scale 
pandemics in the past two decades, SARS and the 
Middle East respiratory syndrome (MERS) (Drosten et al., 
2003; Zaki et al., 2012). It has commonly been thought that 
SARS-CoV-2 which is found in bats could cause a disease 
outbreak (Fan et al., 2019; Schoeman & Fielding, 2019). 
 
ORIGIN OF SARS-CoV-2 
The source of the new coronavirus infection has been 
resolved as a racket. With the entire genome, the SARS-
CoV-2 sequences are 96% identical at the full genome 
level of the interactive Coronavirus (Zhou et al., 2020). Wu 
and his colleagues note a genetic analysis of the genetic 
development of the complete viral genome and conclude 
that the virus was closely related to a group of SARS 
coronaviruses that were previously sampled on bats in 
China (Wu et al., 2020a). Ji and colleagues note a complete 
sequence analysis and comparison in conjunction with 
the relative polarization of the use of equivalent codon 
(RSCU) among animal species based on the SARS-CoV-
2 RNA genome sequences, and results show that the 
virus was a combined virus between a bat coronavirus 
and another unknown origin coronavirus. They also 
noticed that the snake was the animal's most likely 
reservoir due to the RSCU bias of the virus being closest 
to the snake (Ji et al., 2020). The new coronavirus has 
demonstrated a similar pattern of infection with other 
coronaviruses in humans, especially the SARS-CoV and 
MERS-CoV (Guo et al., 2020; Kumar et al., 2020). 
 
COMPOSITION OF SARS-CoV-2 
Coronary viruses are spherical with diameters of 
approximately 125 nm, as demonstrated in recent studies 
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by microscopic tomography and electron microscopy. A 
major characteristic feature of coronaviruses is that club-
dropping points emanate from the surface of the virion. 
These nails are an explanatory feature of the virion and 
give it the appearance of a solar aura, which gave the 
name of a coronavirus. In the shell of the virion is the 
nucleus. Coronaviruses have a unified helical 
nucleocapsid, which is not unusual for positive RNA 
viruses but is more common for negative RNA viruses 
(Barcena et al., 2009). 
The structure of the coronavirus contains four major 
structural proteins as visualized in Figure 4. These are 
advanced proteins (S) membranous proteins (M) casing 
proteins (E) and nucleocapsid proteins (N) all encoded at 
the three 'ends of the viral genome. Protein S (~150 kDa), 
uses the N-terminal signal sequence to access the ER, and 
it is strongly bound to glycosylate. Homotrimers from the 
virus-encoded protein S produce a distinct peak structure 
on the surface of the virus. COVID-19 glycoprotein S 
could be a first-class fusion protein and a successful 
binding to the host receptor. In most coronaviruses, S is 
divided by angry protease in a group of cells into several 
different peptides denoting S1 (receptor binding 
domains) and S2 (advanced molecule) (Schoeman & 
Fielding, 2019). 
 
Figure 4. Schematic diagram of coronavirus present different 
membrane proteins 
 
Protein M is the most abundant structural protein in 
Freon. It is a very weak protein (~25-30 kDa) with three 
membranous domains (Molenkamp & Spaan, 1997) and 
is supposed to transport virion in its shape. It is a low 
ectodomain N-terminal glycosylated and a much larger 
C-terminal endo domain extends 6 to 8 nm in the viral 
structure (Kuo & Masters, 2013). Although the translation 
is common to the ER membrane, most M proteins do not 
have the code sequence (Hurst et al., 2013). 
Protein E (~8-12 kDa) is found in small quantities in the 
Freon. Coronavirus E proteins vary greatly but have a 
typical structure (Sturman et al., 1980). The membrane 
topology for protein E has not been completely resolved, 
but most data indicate that it is a transmembrane protein. 
Protein E contains the ectoderm N-terminal field and the 
C-terminal endodomain and the ion channel activity. 
Since they are hostile to other structural proteins, 
recombinant viruses that lack protein E are not always 
fatal, although this may depend on the type of virus 
(Klausegger et al., 1999).  
Protein N is the only protein found in the nucleus. It 
consists of two different fields, the N-domain (NTD) and 
the C-field (CTD), both of which can bind to RNA in the 
laboratory, but each field uses different mechanisms to 
link RNA. Protein N is also graters phosphorylated, and 
phosphorylation has been recommended to make a 
structural change that improves viral RNA affinity 
compared to non-viral RNA. Protein N links the viral 
genome with string-like beads. Specific cRNAs 
substrates were identified for protein N; TRS and 
genomic packing signal. Genomic conditioning signal is 
individually associated with the second domain or the 
terminal RNA binding field. N protein also binds nsp3 
receptor protein, a key component of the replicate 
complex protein, and the M protein (McBride et al., 2014). 
A fifth structural protein, hemagglutinin esterase (HE), is 
here in a subset of β-CoV. Protein works like 
hemagglutinin bind to sialic acids with glycoproteins on 
the surface and contains acetyl esterase activity (Graham 
et al., 2005). These activities are believed to prolong the 
entry of cells by protein S and the spread of the virus 
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through the mucosa (Cornillez-Ty et al., 2009). 
Interestingly, it increases the nerve idling of the viral 
hepatitis virus (MHV) (Chatterjee et al., 2009); however, 
he chooses against tissue culture for unknown reasons 
(Egloff et al., 2006). 
The ORF1a/b consists of about two-thirds of the viral 
genome and codes for 16 non-structural proteins as 
summarized in Table I. There is a shift in Box-1 between 
ORF1a and ORF1b, which results in the production of 
two peptides (pp1a and pp1ab), which are then 
processed by the viral coded protease at 16 nsp. 
Table I. Function of non-structural protein of SARS-CoV-2s 
Protein Function References 
NSP 1 Promote cellular mRNA 
degradation with the 
translation of the host 
cells prevent innate 
immune response 
Eriksson et al., 2008; 
Frieman et al., 2009 
NSP 2 There is no known 
function, linked to the 
prohibition of proteins 
Serrano et al., 2009; 
Ziebuhr et al., 2001 
NSP 3 Multidomain larger 
transmembrane proteins 
interact with activities 
with protein N, promote 
the expression of 
cytokines, attach to the 
viral protein, and block 
the host's innate 
immune response.  
Gadlage et al., 2010; 
Oostra et al., 2008; 
Egloff et al., 2004 
NSP 4 Potential membrane 
scaffold protein 
responsible for 
providing suitable 
structure for DMVs 
Xu et al., 2003 
NSP 5 Mpro cleans viral 
polyprotein 
Ivanov & Ziebuhr, 
2004 
NSP 6 Potential membrane 
scaffold protein from 
transliterating viral 
protein. 
Ivanov et al., 2004 
NSP 7 The formation of a super 
complex hexadecameric 
with nsp8 could serve as 
a practical clamp for 
RNA polymerase  
Eckerle et al., 2010 
NSP 8 The formation of a super 
complex hexadecameric 
with nsp7 could serve as 
a practical clamp for 
RNA polymerase  
Eckerle et al., 2007 
NSP 9 Host-based RNA 
binding protein 
Chen et al., 2019 
NSP 10 The cofactor of nsp16 
and nsp14 forms 
heterogeneous 
modulator with both 
and enhance Exon and 
2-O-MT activity 
Bhardwaj et al., 
2006 
NSP 11 Cleavage of pp1a at the 
NSP 10/12 junction 
Decroly et al., 2008 
NSP 12 RNA-dependent RNA 
polymerase, RdRp 
(enzyme activity) 
Decroly et al., 2008 
NSP 13 Nucleoside 
Triphosphatase 
(NTPase enzyme) 
activities 
Züst et al., 2011; 
Cheng & Shan, 
2020 
NSP 14 N7-MTase activities of 
viral genomes 
Chen et al., 2019 
NSP 15 The major role of NSP 15 
in coronavirus 
replication 
Bhardwaj et al., 
2004 
NSP 16 2′-O-MT (ribose 2′-O-
methyltransferase) 
activity 
Decroly et al., 2011 
 
TRANSMISSION ROUTES OF SARS-CoV-
2 
The coronavirus first announced in December 2019 is 
now a public health emergency of international concern. 
Epidemiologists are working to update estimates the 
number of cases; genome samples of the pathogen are 
being sequenced and results are being shared (Zheng, 
2020). Mechanisms of transmission are concluding to 
incorporate contact, droplet, and possibly airborne under 
certain circumstances supported on historical 
experiences associated with SARS-CoV outbreaks (Yu et 
al., 2020; Christian et al., 2004). 
Respiratory droplet 
Respiratory infection may be transmitted through 
droplets of varied sizes; when the droplet partials are 
smaller than 5-10 µm in diameter, they called respiratory 
droplets, and after they are smaller than 5 µm in diameter 
they’re called as droplet nuclei, per present evidence, 
COVID-19 virus is primarily transmitted between people 
through respiratory droplets and parson to parson close 
contact routes. Droplet spread occurs when an individual 
is in close contact (within a minute) with people who 
have respiratory symptoms (e.g. coughing or sneezing) 
and is therefore in danger of getting his/her mucosa 
(mouth and nose) or conjunctive (eyes) exposed to 
potentially infective respiratory droplets. Transmission 
can also occur through fomites with the immediate 
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environment around the infected parson (Dbouk & 
Drikakis, 2020). 
Focal-oral routes 
There is some evidence that COVID-19 infection may 
attend to intestinal infection and be present in fasces. 
However, thus for just one study has cultured the 
COVID-19 virus from one stool specimen (Zhang et al., 
2020a). There are no announced of fecal-oral transmission 
of the COVID-19 virus thus for. The fundamental 
reproduction number (R0) for this infection, given 
variable host and environmental factors, is measurement 
within the initial outbreak to be between 2.2 and 3.6 
(number of cases generated after exposure to at least one 
patient), which is said to SARS-CoV but on top of MERS-
CoV (Zhao et al., 2020). 
People who live or travel a lot in Hubei province are at 
risk of infection. Also, doctors and health officials who are 
infected to new coronavirus patients have a good chance 
of contracting the virus, despite appropriate preventive 
measures. One of the first signs of transmission between 
people is health care providers who develop the disease. 
 
PATHOGENESIS OF COVID-19 
The pathogenesis of COVID-19 infection is mostly 
related to the depletion of type 2 respiratory pneumocyte 
cells resulting in profound alveoli destruction as 
visualized in Figure 5. 
Selective tropism for pneumocyte molecular receptor 
The first coronavirus receptors were identified by the 
MHV receptor as listed in Table II. The MHV binds to 
the Murine carcinoembryonic antigens related adhesion 
molecule 1 (mCEACAM1) adhesion molecule (the 
adhesion molecule of membranous cancer cell antigen) to 
cell injury. The mCEACAM1 can be a type I membrane 
protein linked to the immunoglobulin superfamily. The 
mCEACAM1 can be a multifunctional protein that has 
manic roles in cell adhesion and signaling, among other 
things. Ectodomain of mCEACAM1 has four established 
causes of IgM such as domains, N, A1, B, and A2. The 
mCEACAM1's N-terminal N field shares the MHV 
connection (Belouzard et al., 2012). 
The intervention of the virus at the site of binding of 
receptors 
The entry of the encapsulated virus may occur directly on 
the cell surface after attachment to the receptor or after its 
absorption by the multiplication of cells with fusion in the 
endosomal chamber. The fusion of viral membranes with 
the host membranes occurs due to the large 
corresponding changes in the peak of the protein. Over 
time, coronaviruses modified their climax of proteins, 
resulting in a group of catalysts that would not activate 
their fusion. These matching changes will begin by 
binding to the receptor but may have additional catalysts 
such as pH acidification or protein activation (Cheng et 
al., 2004). 
Table II. Different types of receptors proteins presence of 
different coronavirus species 
Classes 
of Virus 
Species Receptor References 
α-CoV TGEV Aminopeptidase 
N (APN) 
Delmas et al., 
1992 
CCoV 
 
APN Benbacer et 
al., 1997 
FeCoV 
 
APN Tresnan et al., 
1996 
PEDV 
 
APN Li et al., 2007 
HCoV-
229E 
APN Yeager et al., 
1992 
HCoV-
NL63 
Angiotensin-
converting 
enzyme 2 (ACE2) 
Hofmann et 
al., 2005 
β-CoV BCoV 
 
N-acetyl-9-O-
acetylneuraminic 
acid 
Schultze & 
Herrler, 1992 
 
MHV Murine 
carcinoembryonic 
antigens related 
adhesion 
molecule 1 
(mCEACAM) 
Nedellec et 
al., 1994; 
Williams et 
al., 1991 
SARS-
CoV 
ACE2 Li et al., 2003 
MERS-
CoV 
Dipeptidyl 
peptidase 4 
(DPP4) 
Raj et al., 2013 
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Integration of viral DNA into the host cell 
The primary association of virion with the host cell begins 
with interactions between protein S and its receptor. 
Recipient binding domain (RBD) sites within the S1 
protein S site of the coronavirus vary depending on the 
virus, some have RBD at the end N of S1 (MHV), while 
others SARS-CoV have an RBD at the C term of S1 
(Krijnse-Locker et al., 1994). The interaction of S protein 
receptors is the primary determinant of coronaviruses to 
infect host species and also leads to polarization of the 
virus tissue. SARS-CoV and HCoV-NL63 use the ACE2 
as a receptor, enter the MHV via mCEACAM1, and 
connect the newly identified MERS-CoV with dipeptidyl 
peptidase 4 (DPP4) to enter human cells as presented in 
Table II. 
Repetition 
The next step in the life cycle of a coronavirus is to 
translate the mimic gene from the viral genomic RNA. 
The gene codes for two large ORFs, rep1a and rep1b, 
which connect to two homogeneous polypropylene 
proteins, pp1a and pp1ab. To deliver multiple proteins, 
the virus uses a sliding sequence (5'-UUUAAAC-3') and 
RNA pseudoknot that causes the displacement of the 
ribosome frame from the rep1a reading frame towards 
the ORF rep1b. In most cases, the ribosome breaks down 
the pseudoknot structure and extends the translation 
until it satisfies colonic stop code 1. Sometimes, the false 
node prevents the ribosome from continuing to elongate, 
resulting in a temporary stop in the slippery sequence, 
adjusting the reading frame by moving the nucleotide, 
and turning-1 frame before the ribosome can dissolve the 
pseudoknot structure and extend the translation to 
rep1b, which leads to an interpretation of pp1ab (Cheng 
& Shan, 2020; Yu et al., 2004). 
 
Figure 5. Replication process of SARS-CoV-2 
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Destruction of type 2 respiratory pneumocyte cell 
Viral particles transcribed into the respiratory type 2 lung 
cell begin to form buds forming the cell wall of the host 
cell. When these particles separate from the affected host 
cell, they damage part of the cell membrane of the host 
cell and cause the host cell to die by programmed cell 
death. 
Viral spread 
After reproduction and synthesis of RNA without 
genome, viral structural proteins S, E, and M are 
translated and inserted into the endoplasmic reticulum 
(ER). These proteins travel along the secretory pathway 
in the endoplasmic reticulum - Golgi compartment 
(ERGIC) (Tooze et al., 1984; de Haan & Rottier, 2005).  
There, viral genomes coated with N protein in ERGIC 
membranes contain viral structural proteins, forming 
mature virions (Arons et al., 2020). 
 
SYMPTOMS OF COVID-19 
The maximum number of patients infected with the virus 
will suffer from colds and influenza, while a few will 
remain asymptomatic. About 80% of patients will 
experience mild symptoms of the disease. Adults have 
the best immunity to fight infection, but the disadvantage 
is that they are more likely to spread infection and a 
recent study of nearly 140 patients at Zhong nan Hospital 
of Wuhan University has revealed two different. Types 
of symptoms that lead to a disease known as COVID-19. 
Almost 99% of the patients developed a very hot fever, 
while more than half of them experienced fatigue and a 
dry cough. A third of the patients developed a dry cough 
and difficulty breathing (Yi et al., 2020; Fu et al., 2020). 
 
DIAGNOSIS OF COVID-19 
The diagnosis allows suspects to understand whether 
they are infected or not. Diagnosis can help get the care 
they need and can help them take steps to reduce the 
likelihood of injury to others. If a person develops 
symptoms of coronavirus 2019 and is exposed to the 
virus, he consults a doctor. The doctor can decide 
whether or not to test COVID-19 based on individual 
signs and symptoms. The doctor can also determine if the 
person is in close contact with a person diagnosed with 
COVID-19 or who has visited or lived in areas where the 
community has continued to spread COVID-19 in the 
past 14 days (Jin et al., 2020). 
Direct detection 
The SARS-CoV-2 infection is detected by special 
laboratory tests that require samples such as throat swabs 
or lung fluid. This method is called a PCR test and it takes 
24 to 48 hours to get the final results. WHO recommends 
sampling the upper and lower respiratory tract. This can 
be done with sputum, bronchial lavage, or end-trachea 
sucking. These samples will then determine the viral 
RNA identity using a polymerase chain reaction (PCR). 
If a positive test result is obtained, it is recommended to 
repeat the activation test. Negative tests with strong 
clinical suspicion are also recommended for repeated 
testing (Kumar et al., 2020; Hassan et al., 2020). 
Serological test 
The SARS-CoV ELISA and IgM ELISA Inner control kits 
were developed using IDR 3 N SARS-CoV as antigens, 
which share 90% amino acid alkene identity with all or all 
SARSr-CoVs2. For IgG analysis, the 96-well MaxiSorp 
Nunc-Immuno ELISA sheet (100 ng per well) was coated 
overnight with recombinant N protein. Human sera are 
used at 1:20 dilution for one hour at 37°C. Monoclonal 
antibody IgG HRP (Kyab Biotech) was used at a dilution 
of 1 : 40000. OD value (calculated 450-630 nm). For IgM 
analysis, the 96-well MaxiSorp Nunc-Immuno ELISA 
sheet (500 ng per well) was coated overnight using anti-
human IgM (μ series). Human sera are used at 1 : 100 
dilutions for 40 minutes at 37°C, and then incubated with 
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anti-Rp. 3 N HRP (Kyab Biotech) antibodies at 1: 4,000 
dilutions. OD values  (450) - 630 nm) are calculated (Okba 
et al., 2020). 
RNA vaccines 
Modern Biotechnology Company in Cambridge has 
prepared a test vaccine for coronavirus diagnosis. This 
rapid change is due to the unique advantages of RNA 
vaccines, says MIT Professor Daniel Anderson that the 
main advantage of the RNA message is the speed with 
which you can define and use a new sequence to find a 
new vaccine (World Health Organization, 2020). 
Molecular examinations 
Currently, many of the tests that reveal SARS-CoV-2 are 
prepared internally, commercially, or under 
development. Some tests can only detect the new virus, 
and some tests can also detect other strains that are 
genetically similar (Trafton et al., 2020). 
 
TREATMENT OF COVID-19 
Currently, there is no specific treatment, vaccine, or drug 
for the virus. However, healthcare professionals have 
many ways to help patients. First, early diagnosis helps 
stop the spread of the disease, making society a safer 
place for everyday life. Second, there are supportive care 
options that seem to work miracles with new coronavirus 
patients. 
General treatment 
A confirmed COVID-19 patient needs complete bed rest 
and supportive treatment, ensuring that enough calories 
and fluids are consumed to reduce the risk of 
dehydration. Water and homeostasis must be 
maintained while monitoring vital signs and oxygen 
saturation; keep the airways clean and inhale the oxygen 
in more severe cases; Measure blood count, creative 
protein, urine test and other biochemical blood clues, 
including liver and kidney functions, group of heart 
muscle enzymes, and clotting function depending on 
patient conditions. Chest imaging should be reviewed 
continuously, and blood gas should be analyzed if 
necessary (Zhejiang University School of Medicine, 
2020). 
Symptomatic treatment 
Control measures are needed for patients with a high 
fever. Antipyretic treatment should be done if the 
temperature exceeds 38.5°C. Warm baths and antipyretic 
stains are preferred as a precautionary measure to reduce 
the temperature. Common medications include oral 
ibuprofen, 5-10 mg/kg each; Oral acetaminophen, 10 to 
15 mg/kg at a time (Zhejiang University School of 
Medicine, 2020). 
Oxygen therapy 
The risk of hypoxia increases when the virus targets the 
lungs. A nasal catheter and an oxygen mask should be 
provided to the patient immediately. In an emergency, 
non-invasive or invasive mechanical ventilation should 
be provided to the patient (Shen et al., 2020). 
Antiviral drugs 
Various antiviral drugs, including interferon-alpha (IFN-
α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, 
and arbidol are therapeutically useful for the prevention, 
diagnosis, and treatment of new induced pneumonia by 
SARS-CoV-2 by the National Health Committee (CNS) 
of the People's Republic of China For the temporary 
treatment of COVID-19. IFN-α is a widespread antiviral 
that is usually used to treat hepatitis, although it has been 
reported to prevent SARS reproduction in CoV in vitro. 
IFN-α is given as a vapor twice a day. Fifth editions of the 
guidelines approved antiviral drugs including IFN-α, 
lopinavir/ritonavir, and ribavirin for the treatment of 
COVID-19. Chloroquine is incorporated in the sixth 
version of the guidelines based on preliminary results of 
clinical studies. The specific method for administering 
IFN-α is the inhalation of vapor at a dose of 5 million units 
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(and 2 ml of sterile water for injection) for adults, twice a 
day. The dose of lopinavir/ritonavir is 400 mg/100 mg 
for adults, twice daily. Ribavirin should be administered 
by intravenous infusion at a dose of 500 mg for adults, 2-
3 times/day in combination with IFN-α or 
lopinavir/ritonavir. Oral chloroquine phosphate is 
administered in a dose of 500 mg (300 mg of chloroquine) 
for adults, twice a day. Arbidol is given orally at a dosage 
of 200 mg for adults, three times/day. The duration of 
treatment does not exceed 10 days (Zhang et al., 2020b; 
Wu et al., 2020b). 
Favipiravir is a new drug in clinical trials for the 
treatment of COVID-19. On February 15th, 2020, China 
agreed that it was a useful drug for treating the new flu. 
It works by inhibiting the enzyme-dependent RNA 
polymerase RNA. Favipiravir is transformed into an 
active phosphorylate (favipiravir-RTP) form in cells and 
is recognized as a substrate by viral RNA polymerase, 
thereby inhibiting the activity of RNA polymerase. 
Therefore, favipiravir may have a potent antiviral effect 
on SARS-CoV-2, which is the RNA virus (Yavuz & Unal, 
2020). 
Remdesivir is another investigative drug in the clinical 
trial for the treatment of COVID-19. Remdesivir is a 
broad-spectrum nucleoside and antiviral analog. Animal 
experiments have indicated that remdesivir can 
effectively reduce viral load in lung tissue in mice infected 
with MERS-CoV virus, improve lung function and 
reduce pathological damage to lung tissue (Wu et al., 
2020b; Cao et al., 2020). 
A team of researchers from the Shanghai Materia Medica 
Institute and the Shanghai University of Technology 
conducted silicon drugs and enzyme activity testing and 
reported 30 workers who might have antiviral activity 
against SARS-CoV-2 on January 25th, 2020. These factors 
are indinavir, saquinavir, lopinavir, Carfilzomib, 
ritonavir, remdesivir, atazanavir, darunavir, tipranavir, 
fosamprenavir, enzaplatovir, presatovir, abacavir, 
bortezomib, cyclosporine A and cinanserin. It has also 
been proven that some Chinese herbal medicines such as 
Rhizoma Polygoni Cuspidati and Radix Sophorae 
Tonkinensis contain certain active ingredients that were 
effective against COV-2 (Shen et al., 2020). 
Antibiotic drugs 
The third class of medicinal drugs is Azithromycin, a 
class of antibiotics known as macrolide that is used to 
treat infections such as bronchitis, pneumonia, and MAC 
infection (Mycobacterium avium complex). With the spread 
of SARS-CoV-2, many countries around the world have 
started developing countermeasures to limit the spread 
of the disease. The authors found that in addition to 
hydroxychloroquine, another FDA-approved drug 
known as Azithromycin had therapeutic effects against 
COVID-19 in a study accompanied by a University of 
New Mexico research group (Choudhary & Sharma, 
2020). 
Anti-coagulating therapy 
Hospital patients with severe medical illness are at an 
increased risk of developing VTE up to 90 days after 
discharge. This result should apply to COVID-19 
patients, although infection data don't seem to be yet 
available. Therefore, it is reasonable to think of long blood 
clots occurring after prolonged discharge using a 
regulated approved system (such as betrixaban 160 mg 
on the first day, followed by 80 mg once daily for 35 to 42 
days; or rivaroxaban 10 mg daily for 31 to 39 Days) 
(Porfidia & Pola, 2020). 
Boosts the immune system 
In addition to basic disease prevention and true defense, 
there is a strong immune system. The human body is 
better able to fight disease when the immune system is 
impulsive and people have to get fit to get the perfect 
shape. In this critical condition, get enough sleep and a 
little fresh air and the sun every day. People also need to 
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stay hydrated, reduce excessively processed foods, and 
make sure to eat enough micronutrients when they can 
do their best with what they can find in grocery stores 
right now (Taghizadeh-Hesary & Akbari, 2020). 
 
PREVENTION AND CONTROL OF 
COVID-19 
This new virus often features a limited geographic spread 
(Zappa et al., 2009). However, there are the amounts of 
hygiene measures that are recommended to guard 
against the infection and for the spread the include 
following advisory are covering your mouth and nose 
with masks, avoiding close contact with those that are 
sick, stop shaking hand with one other, washing hands 
regularly after one hour with soap, avoiding unnecessary 
contact with animals and hand washing, use of masks 
and PPE (Personal protective equipment), drinking 
warm water daily, sanitize your hands time to time 
(Singhal, 2020). 
Steps to protect yourself 
1. Wash your hands regularly and completely with 
soap and water for at least 20 seconds or with an 
alcohol-based hand sanitizer (a hand sanitizer that 
contains at least 60% alcohol), rub the cover 
thoroughly together so that it does not dry out, 
especially after visiting a public place, or after 
blowing your nose or sneeze as well as cough. 
2. Hands touch many surfaces and catch viruses, and 
these contaminated hands can spread the virus to 
your nose, eyes, or mouth. So, avoid touching these 
organs with unwashed hands. Because from there, 
the virus can enter the body and make people sick. 
3. Maintain a social distance (keep at least 1 m or 3 feet 
between you and anyone) and avoid close contact 
with patients (who cough or sneeze). When infected 
or sneeze, they spray small drops from their nose or 
mouth that may contain the COVID-19 virus. A 
person can breathe these drops (Centers for Disease 
Control and Prevention, 2020). 
Steps to protect others 
1. Stay home if you are not feeling well unless you will 
get medical treatment. 
2. If you have a cough, fever, and difficulty breathing, 
see your doctor online, see your doctor. 
3. If you are sick, avoid using public transportation. 
4. When you cough or sneeze, cover your mouth and 
nose with a tissue. 
5. Throw used tissue into the trash and wash your 
hands immediately with cleansing water and soap. 
6. If possible, stay isolated in a room separate from 
family and pets and wear a face mask when you are 
with other people (for example, sharing a room or 
car). If you are unable to wear a face mask (for reasons 
related to breathing difficulties or for any other 
reason), you cover coughs and sneezes, but when 
people caring for you enter your room they should 
wear a face mask (face masks may be low in width 
and should be kept for caregivers). 
7. Stay home for some time and follow your doctor's 
instructions. 
8. If you are sick, avoid sharing bedding, dishes, glasses, 
and other household items. 
9. Use a separate bathroom and toilet, if possible. 
10. If the surfaces are dirty, clean them and use 
detergents or antiseptic soaps and water before using 
the disinfectant, 
11. Apply antiseptic daily to frequently affected surfaces. 
This includes offices, telephones, keyboards, toilets, 
faucets, tables, door handles, lighting switches, 
counters, knobs, and basins. 
12. Identify and isolate suspected cases. 
13. Before starting clinical care, identify potential cases as 
soon as possible and isolate suspects separately from 
those who have confirmed cases of COVID-19, to 
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prevent the possible transmission of infection to other 
patients and nursing staff. 
14. Avoid direct physical contact (including physical 
examination and exposure) to other respiratory and 
physical secretions. For example, move the possibility 
of infectious people into isolation rooms and close the 
doors. In the workplace, make the distance between 
workers, clients, and other visitors, especially from 
the location of potentially infectious people. 
15. If there is a need to isolate a patient or a group of 
patients, pharmacies must determine and prepare an 
appropriate space. 
16. Most patients coming to community pharmacies are 
unlikely to have COVID-19. If you have symptoms of 
a cough, cold, or flu-like symptoms, but not related to 
COVID-19, or the date of travel or contact, 
pharmacies should do so following their best 
practices and routine infection risk management. 
Across to other employees and patients. 
17. Restrict the number of individuals entering isolation 
areas, including the bedroom of a patient with 
suspected and confirmed COVID-19. 
18. To practice safe work, protect workers from close 
contact with the affected person using additional 
technical and administrative controls (Occupational 
Safety and Health Administration, 2020). 
 
CONCLUSION 
The COVID-19 pandemic is traveling around the world 
at a dangerous rate. More infections and deaths are 
caused by SARS or ME respiratory syndrome. The R0 
values supported, SARS-CoV-2 assumed more SARS or 
MERS infection. The elderly and HIV-positive patients 
are at greater risk of death. The first outbreak requires 
extensive surveillance and isolation protocols to stop 
transmission. No confirmed drugs or vaccines were 
developed. The first treatment strategies are aimed at 
symptomatic care and oxygen therapy. Preventive 
vaccination is necessary for the long-term prevention of 
epidemics or epidemics associated with the coronavirus. 
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